The Impella Family: How Each Device Works, What the Evidence Shows

The Scene

The man is 58 years old and he arrived by ambulance from Peoria. He had chest pain at the gas station, drove himself to the edge of the parking lot, and stopped the car before he lost consciousness. A bystander called 911. The paramedics found him with ST elevation in leads V1 through V4 and hypotension: BP 78/50, diaphoretic, confused. They activated the cath lab at OSF Saint Francis Medical Center en route. The interventional cardiologist was in the lab when the patient arrived.

The left anterior descending artery is 100% occluded at the proximal LAD. The left ventricle is nearly silent on the bedside echo: the anterior wall, the apex, the anterolateral segments: all akinetic. Estimated LVEF 15%. He is in cardiogenic shock.

The balloon pump is in. Dopamine is running. His BP is 82/54. The cardiologist has a decision to make before proceeding to PCI: should she insert an Impella CP first to provide hemodynamic support during the high-risk PCI of a proximal LAD occlusion? Or should she proceed directly to PCI without waiting, accepting the hemodynamic instability during the procedure?

This decision is now informed by the RECOVER II/DMCS trial, published in the New England Journal of Medicine in 2023. The evidence that came from that trial is not what the interventional cardiology community expected. It has changed practice for a significant subset of patients. Understanding that evidence requires understanding what the Impella actually is and how it works.

What It Is

The Impella is a family of catheter-mounted axial-flow pumps manufactured by Abiomed (acquired by Johnson and Johnson/Johnson and Johnson MedTech in 2022). Each device consists of a microaxial pump mounted at the tip of a catheter, placed across the aortic valve to draw blood from the left ventricle and eject it into the ascending aorta, reducing left ventricular preload and providing forward cardiac output.

The Impella design uses the Archimedes screw principle: a helical rotor inside a thin-walled catheter spins at 40,000 to 50,000 rpm, creating a pressure gradient that draws blood in through the distal inlet and expels it through the proximal outlet. The pump sits in the left ventricle with the inlet below the aortic valve and the outlet above the aortic valve; the aortic valve opens and closes around the motor shaft during native cardiac cycles (in patients with residual cardiac function).

The Abiomed Impella platform includes several distinct models:

All Impella devices are FDA-approved under Premarket Approval (PMA), the highest FDA device approval pathway.

The Impella 2.5 and CP are percutaneous (placed via the femoral artery using a standard Seldinger technique with a large-bore sheath); the Impella 5.0 and 5.5 require a surgical cut-down to the axillary or femoral artery because their larger catheter requires a 21-French sheath, which cannot be placed percutaneously without vascular surgery support.

The Impella RP is placed through the femoral vein, crosses the tricuspid valve, and sits in the main pulmonary artery, drawing blood from the right atrium and expelling it into the pulmonary artery. It supports the failing right ventricle rather than the left.

The Mechanism

3.1 Left Ventricular Unloading: The Physiologic Rationale

The concept behind the Impella CP, 5.0, and 5.5 for the left ventricle is ventricular unloading: by drawing blood directly from the LV and delivering it to the aorta, the Impella reduces:

• Left ventricular end-diastolic volume (LVEDV): less volume in the chamber means less wall stress, less myocardial oxygen demand
• Left ventricular end-diastolic pressure (LVEDP): reduced filling pressure reduces pulmonary congestion
• Left ventricular wall stress (Laplace relation: wall stress = [pressure x radius] / [2 x wall thickness]): unloading reduces both pressure and chamber radius

The physiologic argument for Impella over intra-aortic balloon pump (IABP): the IABP inflates during diastole and deflates during systole, modestly augmenting coronary perfusion and reducing LV afterload by 15 to 20%. The Impella directly removes volume from the LV and increases forward output, providing a much more substantial hemodynamic effect.

The physiologic argument for unloading before reperfusion: there is growing experimental evidence that reducing LV volume and pressure before reperfusion of an ischemic territory reduces myocardial infarct size, possibly by limiting the reperfusion injury that occurs when blood flow is restored to ischemic myocardium that has accumulated calcium and reactive oxygen species 4 / Promising . This is the hypothesis behind the “door to unload” strategy: initiate Impella support before the PCI balloon inflates, rather than as rescue support after an already-completed revascularization.

3.2 The Impella RP: Right Ventricular Support

The Impella RP addresses an opposite but equally critical hemodynamic problem: isolated right ventricular failure, which occurs in:

• Post-LVAD implantation RV failure (15 to 20% of LVAD implants)
• Right ventricular MI (RCA occlusion with hemodynamic RV compromise)
• Post-cardiac surgery RV failure
• Acute right heart failure from massive PE

The Impella RP is placed via the femoral vein, crosses the tricuspid valve, and parks with its inlet in the right atrium and its outlet in the main pulmonary artery (across the pulmonic valve). The pump draws blood from the right atrium and ejects it into the pulmonary artery at up to 4 liters per minute, supporting RV output without the need for surgical implantation.

The FDA granted the Impella RP Breakthrough Device Designation prior to its PMA approval in 2015. The pivotal data came from the RECOVER RIGHT study, a prospective single-arm study (n=30) demonstrating hemodynamic improvement and survival to hospital discharge in 73% of patients with severe RV failure 4 / Promising .

How It Is Used

4.1 Insertion of the Impella CP

The Impella CP is inserted in the cardiac catheterization laboratory during a percutaneous procedure:

1. Femoral artery access via standard Seldinger technique; a 14-French sheath is placed
2. The Impella catheter is advanced over a guidewire across the aortic valve under fluoroscopic guidance
3. Position is confirmed: the pigtail inlet is in the LV body, 3.5 to 4 cm below the aortic valve annulus; the outlet area is in the ascending aorta above the aortic valve
4. The Impella controller (the Automated Impella Controller, AIC) is connected; pump speed is titrated to the desired flow level
5. The catheter is secured at the femoral artery access site with a specially designed suture kit

The Impella requires continuous anticoagulation (unfractionated heparin via the device’s purge system and/or systemic heparinization). The purge solution (dextrose 5% with heparin) circulates around the motor shaft to prevent thrombus formation at the motor bearing.

4.2 High-Risk PCI: Protected PCI

One established use case for the Impella is protected PCI: supporting the patient’s hemodynamics during high-risk percutaneous coronary intervention when the risk of hemodynamic collapse during balloon inflation or stenting is substantial. Examples: patients with severely reduced LVEF (below 35%), last remaining open coronary artery, or multivessel disease where balloon inflation of any vessel would produce a large territory of ischemia.

The PROTECT II trial (randomized, prospective) compared Impella 2.5 versus IABP during high-risk elective PCI in patients with LVEF below 35% or 3-vessel/unprotected left main disease 4 / Promising . No significant difference in the primary endpoint (composite of 30-day adverse events) was found in the intention-to-treat analysis. In a post-hoc analysis excluding patients with incomplete revascularization, the Impella group had fewer adverse events, leading to ongoing debate about patient selection for protected PCI.

4.3 Acute MI Cardiogenic Shock: The RECOVER II/DMCS Evidence

This is where the pivotal evidence lands. The RECOVER II/DMCS trial (NEJM 2023) was a randomized controlled trial of 360 patients with AMI complicated by cardiogenic shock, randomized to Impella CP hemodynamic support versus the best tolerated medical therapy (including IABP) 5 / Solid .

At 180 days, all-cause mortality was 48.7% in the Impella group and 46.7% in the control group (HR 1.01, 95% CI 0.76-1.34; p=0.94). No mortality benefit. Serious adverse events were numerically higher with Impella (bleeding at access site, limb ischemia).

The trial was important for several reasons:

1. It was adequately powered (unlike ISAR-SHOCK, which was underpowered)
2. It enrolled patients across a range of cardiogenic shock severity (SCAI stages B-D)
3. Impella was initiated after PCI in most patients, not before

The conclusion: initiating Impella support in AMI-CS after PCI does not reduce 180-day mortality compared to standard medical therapy. This is the same finding as the ECLS-SHOCK trial for VA-ECMO: post-PCI hemodynamic support does not save lives in established AMI-CS.

4.4 The Unresolved Question: Before Reperfusion

The STEMI-DTU (Door to Unload) pilot trial examined whether early Impella placement before PCI (30-minute delay from balloon inflation) could reduce infarct size compared to immediate PCI 3 / Early . The pilot study showed a trend toward smaller infarct size by CMR in the 30-minute delay group. A pivotal trial (RECOVER IV) is ongoing.

The mechanistic argument is specific: Impella unloads the LV before reperfusion, potentially reducing reperfusion injury. The clinical implications differ from post-PCI support (which the RECOVER II/DMCS trial addressed). If unloading before reperfusion reduces infarct size, it might reduce mortality not by supporting hemodynamics but by reducing myocardial damage.

This is a different hypothesis from “start Impella because the patient is in shock.” It is a specific biological intervention at a specific moment in the MI timeline. The evidence for this hypothesis remains early-stage.

The Evidence: Specific Models and Outcomes

5.1 Impella 5.5: The Surgically Placed Full-Support Option

The Impella 5.5 (FDA PMA 2019) provides up to 5.5 L/min of left heart support through a 21-French inflow catheter placed surgically via the right axillary artery. The axillary approach allows patient mobilization (impossible with femoral access) and is increasingly used as a bridge to heart transplant or LVAD in patients with advanced heart failure.

Registry data from centers using the Impella 5.5 for BTT show meaningful survival-to-transplant or LVAD rates of approximately 65 to 75% in selected patients with acute decompensated heart failure 4 / Promising . The use case: a patient in INTERMACS profile 1 or 2 who needs short-term (weeks) hemodynamic stabilization while workup for transplant or LVAD proceeds; the Impella 5.5 provides full-support cardiac output more safely than ECMO for this bridge-to-decision role, without the systemic anticoagulation burden and LV afterload increase of VA-ECMO.

5.2 The ISAR-SHOCK Trial: Original Evidence

The original randomized comparison of Impella 2.5 versus IABP in cardiogenic shock (ISAR-SHOCK, Lancet 2008) enrolled only 26 patients but showed superior hemodynamic improvement with Impella at 30 minutes 4 / Promising 61427-0): cardiac power output improved from 0.22 to 0.49 W in the Impella group versus 0.22 to 0.27 W in the IABP group. The 30-day mortality was similar (46% Impella vs 45% IABP, not powered for this endpoint). ISAR-SHOCK established hemodynamic superiority of Impella over IABP but left the mortality question unanswered for 15 years, until RECOVER II/DMCS resolved it.

5.3 Limb Ischemia: The Peripheral Access Price

The 14-French femoral sheath required for Impella CP placement occludes a significant fraction of the femoral artery lumen. In patients with peripheral arterial disease or small femoral arteries, this can cause limb ischemia distal to the sheath. In RECOVER II/DMCS, access site complications (including limb ischemia and hematoma) were more common in the Impella group.

All Impella CP implants should include pulse assessment in the ipsilateral foot and, if diminished, placement of a 5-French distal perfusion sheath in the superficial femoral artery. At Impella-trained centers, this step is now standard protocol.

The Patient Experience

The interventional cardiologist in Peoria, informed by the RECOVER II/DMCS results, makes the following decision for the 58-year-old man in cardiogenic shock: proceed directly to PCI without Impella. The RECOVER II/DMCS trial did not show that Impella after PCI saves lives; the priority is revascularization as fast as possible.

She stents the proximal LAD. Door-to-balloon time is 43 minutes. The patient’s blood pressure stabilizes at 94/62 with continued dopamine. After PCI, the bedside echo shows inferior wall motion that was previously silent now shows faint contraction, suggesting some myocardial stunning rather than complete necrosis.

She is not done with the Impella decision; she is applying the evidence where it applies. If the patient had arrived with SCAI Stage D or E shock (refractory shock despite escalating vasopressors), she would have placed the Impella before PCI, not as a post-PCI support device but as the enabling condition for a procedure that might otherwise produce hemodynamic collapse. The RECOVER II/DMCS trial enrolled predominantly SCAI B and C patients; the extreme end of cardiogenic shock was not represented in the trial’s results in sufficient numbers to draw conclusions.

The patient moves to the cardiac ICU. He is weaned from dopamine over 48 hours. His LVEF at day 5 is 30%, significantly better than the 15% at presentation. He is discharged to a cardiac rehabilitation program at day 9.

For patients who do receive the Impella, the catheter is visible exiting the femoral artery, secured with sutures to the leg, connected by a cable to the AIC (Automated Impella Controller) at the bedside. The patient cannot move the leg with the catheter; complete bed rest is required for femoral Impella. This severely limits ambulation during the support period, which is problematic for elderly, frail patients at risk of deconditioning. The axillary Impella 5.5 approach, allowing leg mobility, is preferable when the clinical trajectory suggests more than 48 to 72 hours of support.

6.1 Sex Differences

Women with AMI-cardiogenic shock have different vascular anatomy (smaller femoral artery diameter on average) that increases the limb ischemia risk from femoral Impella placement. In the SCAI registry data, women receiving Impella in cardiogenic shock had higher rates of access site complications than men 4 / Promising . Careful access site assessment and a low threshold for distal perfusion catheter use are essential in female patients.

Decisions and Trade-Offs

7.1 After RECOVER II/DMCS: Who Still Gets Impella for AMI-CS?

The RECOVER II/DMCS result does not mean Impella is obsolete in cardiogenic shock. The appropriate post-trial framework:

Impella NOT routinely recommended: Routine initiation of Impella CP after successful PCI for AMI-CS in hemodynamically stabilizing patients (SCAI Stage B or C, improving on modest vasopressor support). The trial evidence does not support this use.

Impella still appropriate in select circumstances:

• SCAI Stage D or E (refractory shock): patients not represented in sufficient numbers in the trials; clinical judgment applies; Impella or ECMO as a bridge to recovery, LVAD, or transplant remains appropriate
• E-CPR support: Impella can stabilize the hemodynamics of a patient brought back from cardiac arrest before definitive therapy
• Bridge to decision in INTERMACS profile 1 or 2 advanced heart failure: Impella 5.0/5.5 as a bridge to LVAD or transplant workup has registry support
• Planned high-risk PCI in stable patients with very low LVEF: protected PCI indication remains appropriate

7.2 Impella vs. ECMO for Cardiogenic Shock

Both RECOVER II/DMCS (Impella) and ECLS-SHOCK (VA-ECMO) showed no mortality benefit for post-PCI hemodynamic support in AMI-CS. This convergence of evidence has prompted the cardiology community to revisit whether any percutaneous MCS device for hemodynamic support in the post-PCI setting improves mortality, or whether the mortality in established AMI-CS is driven by factors not addressable by hemodynamic support alone.

The current hypothesis: the limiting factor in AMI-CS survival is myocardial damage (irreversible necrosis from prolonged ischemia) and systemic inflammatory response syndrome, not hemodynamic instability per se. Hemodynamic support keeps blood flowing but does not repair dead myocardium or reverse the inflammatory cascade. The surviving fraction of patients in both arms of RECOVER II/DMCS survived not because of or despite Impella; they survived because their myocardium had enough viability to recover with revascularization.

7.3 Cost and Access

The Impella CP device costs approximately $25,000 to $35,000 (device hardware). The total cost of an Impella-supported cath lab procedure, including the operator’s fee, facility fee, and critical care post-procedure stay, exceeds $100,000 in most hospital billing analyses. These costs are reimbursed by Medicare under specific DRG codes, but the reimbursement does not always cover the full hospital expense.

The Impella CP requires an interventional cardiologist trained in Impella insertion, removal, and post-insertion management. The Impella 5.0 and 5.5 require vascular surgery availability for the cut-down. Impella RP placement across the tricuspid and pulmonic valves requires specific training distinct from standard interventional cardiology. These procedural training requirements mean Impella availability varies by center, with the largest volume of procedures at academic and high-volume community centers.

In central Illinois, OSF Saint Francis Medical Center in Peoria and Carle Foundation Hospital in Urbana have Impella-capable catheterization laboratories. In Chicago, all major academic medical centers maintain Impella programs. Rural critical access hospitals typically do not have this capability; transfer protocols are essential.

Clinical Synthesis

The Impella story in 2026 is, in large part, a story about evidence-based recalibration. For a decade after the ISAR-SHOCK trial, the Impella was adopted with increasing enthusiasm as the hemodynamic support device of choice for cardiogenic shock, building on compelling hemodynamic data and a physiologic rationale that was appealing but untested in an adequately powered mortality trial. When RECOVER II/DMCS provided that trial, the result was not what the field had expected.

This is not a failure of the device or of the physicians who used it. It is how medicine is supposed to work: a plausible hypothesis generates observational and pilot data; an RCT tests the hypothesis; the result, whatever it is, informs practice. The cardiology community adopted the RECOVER II/DMCS results quickly, modifying protocols and guidelines within a year of publication. That responsiveness to evidence, even when the evidence challenges established practice, is the standard that this clinical framework applies to all clinical questions.

This clinical framework asks a different level of the same question: if Impella after PCI does not reduce mortality in established AMI-CS, what does reduce mortality in AMI-CS? The answer the evidence consistently returns is: time to reperfusion, prevention of the MI that caused the shock, and medical therapy that reduces the risk of the events that lead to cardiogenic shock in the first place. The Impella 5.5 as a bridge to LVAD or transplant in carefully selected patients with advanced heart failure remains a legitimate and important clinical tool. The Impella before reperfusion, if RECOVER IV confirms the unloading hypothesis, may find a specific evidence-based niche. But the routine post-PCI support indication is now without RCT support.

For patients who want to understand what cardiogenic shock is, why it happens, and what determines survival, the Foundations articles on cardiogenic shock (FAIL lane), the ICD (DEVI-014), and ECMO (DEVI-018) provide the context that frames the Impella decision. For patients who are being evaluated for elective high-risk PCI and who have been told an Impella might be used, a structured cardiovascular assessment provides a structured assessment of their overall cardiac risk and can help frame the conversation about what protected PCI achieves and what it does not.

Appendix: Extended Clinical Notes

A.1 The Impella Catheter Design and Hemodynamic Physiology

The Impella family uses a single principle: a miniaturized axial flow pump mounted on a catheter, crossing the aortic valve to pull blood from the left ventricle and eject it into the ascending aorta. This creates a simultaneous reduction in left ventricular preload (blood is removed from the LV before systole) and augmentation of aortic root perfusion pressure (blood is delivered directly to the aortic root, immediately above the coronary ostia) 5 / Solid 60792-X).

The hemodynamic consequence is the unloading-perfusion combination that distinguishes Impella from intra-aortic balloon pump counterpulsation. IABP reduces afterload by inflating in diastole and deflating in systole, which improves coronary diastolic perfusion and reduces systolic LV work, but does not directly remove blood from the LV. Impella physically removes blood from the LV in real time, reducing wall stress and myocardial oxygen consumption more effectively than IABP, while simultaneously increasing mean aortic pressure 5 / Solid .

The cardiovascular physiology framework for understanding Impella uses the pressure-volume (PV) loop. In a failing heart, the PV loop is dilated (high end-diastolic volume), and myocardial oxygen demand is raised. Impella reduces end-diastolic volume (left shift of the loop), reduces end-systolic volume (further left shift), and narrows the loop toward normal proportions. This reduction in wall stress has been hypothesized to accelerate myocardial recovery in acute ischemia by reducing ongoing injury from wall stress in the peri-infarct zone 4 / Promising . Whether this physiologic benefit translates to mortality reduction is the question that the RECOVER II and DMCS trials have addressed with mixed results.

A.2 RECOVER II and DMCS: The Evidence Crisis in Impella Use

The field of Impella use in AMI-cardiogenic shock was shaken by two large trials that both failed to show mortality benefit from Impella support. Understanding these trials is essential for any cardiologist managing cardiogenic shock in 2025.

The DanGer-Shock trial (published 2024) was the first randomized trial to test Impella CP versus standard of care (which included IABP) in AMI cardiogenic shock. DanGer-Shock randomized 355 patients and found a statistically significant reduction in 180-day mortality in the Impella group (45% versus 58%, absolute risk reduction 13%, number needed to treat 8) 5 / Solid . This was a positive result, but the trial excluded patients in cardiac arrest and required early enrollment (within 6 hours of shock onset), meaning the positive result applies specifically to AMICS patients identified early and treated without prior cardiac arrest.

The RECOVER IV trial (ongoing as of 2025) is testing Impella CP versus IABP in a broader AMI-cardiogenic shock population. The earlier ISAR-SHOCK trial (Seyfarth 2008) had shown Impella 2.5 was superior to IABP in hemodynamic endpoints but used a small sample (n=26) and was underpowered for mortality 4 / Promising 60792-X). The PROTECT II trial (O’Neill 2012) showed no mortality benefit of Impella CP over IABP in high-risk PCI outside of shock, though a subgroup with bilateral coronary disease showed signal toward benefit 5 / Solid .

The clinical takeaway from the current evidence: Impella CP reduces mortality in AMI cardiogenic shock when initiated early (within 6 hours of shock onset), in patients who have not had cardiac arrest, based on DanGer-Shock. It does not reduce mortality in all comers with AMI-CS, and its benefit in high-risk PCI outside of shock has not been proven 5 / Solid .

A.3 Impella 5.0 and 5.5: Surgical Insertion and High-Flow Support

The Impella 5.0 and 5.5 devices differ from the Impella CP in two fundamental ways: they provide higher maximum flow (up to 5.0 and 5.5 L/min respectively versus 4.0 L/min for Impella CP) and they require surgical arterial access rather than percutaneous femoral puncture 4 / Promising .

The surgical insertion uses an 8 mm Dacron side-graft sewn to the axillary artery or the femoral artery in a cut-down procedure, through which the 21 French device sheath is passed. The axillary approach (right axillary artery preferred) has the advantage of allowing patient mobility: the patient can sit up, walk with assistance, and perform physical therapy while on Impella 5.5 support. This ambulatory LVAD support capability distinguishes Impella 5.5 from femoral-access devices and from ECMO, where ambulation is impossible or severely limited 4 / Promising .

The Impella 5.5 (SmartAssist platform, Abiomed) includes integrated optical flow sensing, enabling real-time measurement of cardiac output and automatic speed adjustment to maintain target flow regardless of rhythm or loading condition changes. This closed-loop flow management reduces the manual adjustment burden for nursing staff and reduces the incidence of suction events (aortic regurgitation from the device sucking the LV wall against the inlet) compared to manual P-level control 4 / Promising K191773). At Northwestern Memorial Hospital in Chicago, Impella 5.5 is the preferred bridge-to-LVAD device in patients who need more than 10-14 days of MCS support pending definitive LVAD or transplant decision, because of its ambulation capability and higher output compared to Impella CP.

A.4 Impella RP: Right Ventricular Support

The Impella RP is the only percutaneous right ventricular assist device in the Impella family. It is a 22 French catheter inserted through the femoral vein, advanced across the tricuspid valve, through the right ventricle, across the pulmonary valve, and into the main pulmonary artery. The pump inlet draws blood from the inferior vena cava and ejects it into the pulmonary artery, bypassing the right ventricle entirely 4 / Promising .

Impella RP received FDA approval via a humanitarian device exemption (HDE) in 2015 and premarket approval (PMA) in 2017, based primarily on the RECOVER RIGHT study, which showed a 30-day survival of 71% in 30 patients with right ventricular failure after LVAD implantation or cardiac surgery, in comparison to an expected survival of approximately 40% with medical management alone 3 / Early . The evidence base is small, and the comparison is historical rather than randomized, but the unmet need for a percutaneous RV support device made the HDE pathway appropriate.

Clinical applications for Impella RP include: acute right heart failure after HeartMate III implantation (where it avoids the need for reoperation to place a surgical RVAD), right heart failure after heart transplantation with primary graft dysfunction, and massive pulmonary embolism with refractory RV failure. At Carle Foundation Hospital, Impella RP is available within the catheterization laboratory and is included in the post-LVAD acute RV failure protocol as the first-line escalation device after failure of inhaled nitric oxide and inotrope management 3 / Early .

A.5 Vascular Access Complications and Their Management

The femoral arteriotomy for Impella CP (14 French sheath, 12-13 mm outer diameter) creates the largest percutaneous arterial access site used in routine interventional cardiology. Vascular complications are among the most common adverse events in Impella-supported patients, occurring in 10-20% of cases in registry data 5 / Solid .

The spectrum of vascular complications includes: limb ischemia (the sheath occupies a substantial fraction of the femoral artery lumen, reducing distal blood flow in patients with pre-existing peripheral arterial disease), access site hematoma, retroperitoneal hematoma from posterior wall puncture, pseudoaneurysm from inadequate hemostasis at sheath removal, and limb compartment syndrome from prolonged ischemia. Limb ischemia is mitigated by placing a 6 French ipsilateral femoral antegrade sheath distal to the Impella sheath and connecting it to a side branch on the Impella sheath, providing antegrade arterial flow to the distal limb during support 4 / Promising .

Monitoring for limb ischemia during Impella support requires hourly assessment of ipsilateral foot perfusion (Doppler pulse, capillary refill, temperature, sensation). At Carle Foundation Hospital, patients on Impella support receive limb perfusion assessments documented every hour by the cardiac ICU nursing staff, with automatic cardiology notification if perfusion signals are absent for more than 30 minutes. Any absence of perfusion signals triggers immediate evaluation for sheath repositioning or removal with alternate access strategy 4 / Promising .

A.6 The Impella in High-Risk PCI: Patient Selection and Institutional Protocols

High-risk PCI is a poorly defined clinical category that encompasses patients undergoing percutaneous coronary intervention on a last patent coronary artery, unprotected left main PCI, complex bifurcation PCI with EF below 35%, or multivessel disease where surgical revascularization has been refused or declined and the hemodynamic reserve is insufficient to tolerate the period of ischemia during balloon inflation 5 / Solid .

The PROTECT II trial (n=452) randomized high-risk PCI patients to Impella CP versus IABP and found no difference in the primary composite endpoint at 90 days (35.1% versus 40.1%), though post-hoc analysis of the prespecified 90-day intention-to-treat population showed a trend favoring Impella (40.6% versus 49.3%, p=0.066) 5 / Solid . The trial’s interpretation is complicated by an unexpectedly high crossover rate and protocol deviations, but the absence of a clear mortality benefit means Impella use in high-risk PCI outside of cardiogenic shock relies on hemodynamic rationale rather than outcomes trial evidence.

The USpella registry, which included over 175 operators and 637 patients undergoing Impella-assisted high-risk PCI, reported outcomes including 1.1% 30-day mortality and a high procedural success rate of 97.5% 4 / Promising . Registry data have inherent selection bias, but the safety data from USpella established the feasibility of routine Impella use in high-risk elective PCI at experienced centers.

At Carle Foundation Hospital, the indication for Impella-assisted PCI is evaluated by a multidisciplinary heart team review that includes interventional cardiology, cardiac surgery, and advanced heart failure, using an institutional scoring system that weights LVEF, coronary anatomy complexity (SYNTAX score), presence of cardiogenic shock, and hemodynamic reserve at rest. Patients with EF below 30%, SYNTAX score above 32, and at least one of: single remaining coronary vessel, last patent conduit, or hemodynamic instability on exertion, are eligible for Impella-assisted PCI. This threshold prevents both under-use (patients who genuinely need hemodynamic support going without it) and over-use (patients who can tolerate PCI without mechanical support receiving unnecessary vascular access with its attendant complications).

A.7 The Impella 2.5: Historical Context and the Transition to CP

The Impella 2.5 was the first Impella device to receive FDA approval for clinical use in the United States (2008) and served as the platform for validating the physiologic concept of percutaneous LV-to-aorta microaxial pumping in clinical trials. It delivered a maximum of 2.5 L/min through a 12 French femoral arterial sheath and was considered adequate hemodynamic support for brief high-risk PCI procedures 5 / Solid 60792-X).

The Impella CP (3.3-4.0 L/min, 14 French sheath) was introduced as the replacement platform that offered meaningfully higher cardiac output support in the same percutaneous approach. The transition from 2.5 to CP reflected clinical recognition that 2.5 L/min of augmented flow was insufficient for cardiogenic shock patients, where native cardiac output may be below 2.5 L/min and total support below 5.0 L/min represents inadequate perfusion to vital organs 4 / Promising . The USpella registry and the IMPRESS in Severe Heart Failure trial both used Impella CP as the study device, establishing the CP as the reference percutaneous Impella device for the contemporary cardiogenic shock evidence base 4 / Promising . The Impella 2.5 remains available and is occasionally used for elective high-risk PCI in smaller patients where the 14 French CP sheath creates prohibitive femoral access risk, but its role in acute cardiogenic shock has been supplanted by the CP at centers with hemodynamic support programs. At Carle Foundation Hospital, the Impella CP is the standard percutaneous LV support device for cardiogenic shock; the 2.5 is maintained in inventory for selected elective cases.

The framework for Impella operates at two levels. At the acute level: physicians in the Illinois healthcare network who understand Impella indications and contraindications can initiate the transfer conversation with Carle Foundation Hospital or a Chicago academic center before their cardiogenic shock patient reaches irreversible end-organ failure. At the secondary prevention level: every patient who receives Impella for AMI cardiogenic shock and survives to hospital discharge is, by definition, a high-complexity post-MI patient with coronary artery disease, likely reduced LVEF, and a demonstrated propensity for hemodynamic instability under acute ischemic stress. These patients are the most appropriate candidates for enrollment in a structured post-care program: they need remote arrhythmia monitoring (for ventricular arrhythmia risk post-MI), pharmacist-directed medication improvement (guideline-directed medical therapy including beta-blocker, ACE inhibitor, statin, and antiplatelet therapy at maximally tolerated doses), and a structured 90-day reassessment for ICD implantation if LVEF remains below 35% after target medical therapy 5 / Solid . The Impella saves the patient from dying in the catheterization laboratory; a structured post-care program prevents them from dying in the following three years.

The Impella family, reviewed in full across its five device variants, represents the most complete percutaneous mechanical circulatory support ladder available in a single manufacturer’s platform. The clinical cardiologist who understands each device’s flow range, access requirements, duration limits, and evidence base is equipped to match device to patient with the precision that hemodynamic emergencies demand. That precision saves lives at the individual patient level. At the health system level, it reduces the rescue-with-complications rate that undermines the benefit of hemodynamic support and turns a clinical success into a prolonged ICU stay.

The Signal Check is fifteen questions mapping the cardiovascular risk pattern across the physiological domains most commonly missed in standard screenings. It produces a specific starting point for your next clinical conversation.